Aldara gets FDA nod to treat Actinic Keratoses

Article

Washington - The U.S. Food and Drug Administration (FDA) has granted marketing approval for Aldara (imiquimod) Cream 5 percent for the treatment of actinic keratoses (AK) on the face or scalp in immunocompetent adults.

Related Videos
Related Content

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

DEF and SDPA Partner to Emphasize Cardiovascular Health for World Heart Day

September 29th 2023

Discovering Dermatology Times: September 2023

September 28th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

DEF and SDPA Partner to Emphasize Cardiovascular Health for World Heart Day

September 29th 2023

Discovering Dermatology Times: September 2023

September 28th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

DEF and SDPA Partner to Emphasize Cardiovascular Health for World Heart Day

September 29th 2023

Discovering Dermatology Times: September 2023

September 28th 2023
© 2023 MJH Life Sciences

All rights reserved.